Scarica l'app Stockscreener
5.40
0.80%
0.42
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to sales forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to book forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CNSP) - TradingView
BE50 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNSP Forecast — Price Target — Prediction for 2027 - TradingView
CNS Pharmaceuticals (CNSP) Slides 4.7% as Biotech Sentiment Wavers; Support at $3.84 in FocusFRAMA Signal - dars.gov.et
SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal - BioWorld News
ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics - PR Newswire
Why did CNSP stock surge 330% today? - MSN
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNS Pharmaceuticals Inc (CNSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - Benzinga
CNS Pharmaceuticals (CNSP) Surges 2.45% as Biotech Stock Tests Key ResistanceDark Pool Sentiment - dars.gov.et
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
What's going on with CNS Pharmaceuticals stock on Wednesday? - MSN
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
CNS Pharmaceuticals (CNSP) Shows Resilience with 2% Gain, Testing Key ResistanceSeasonality Effect - newsline.com
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - newsline.com
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
CNS Pharmaceuticals Surges 11% as Biotech Sector Shows Renewed InterestDeath Cross - The Legal Advocate
CNS Pharmaceuticals (CNSP) Faces Selling Pressure as Shares Decline Over 5%Total Put Call - The Legal Advocate
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnEarnings Cycle Outlook - newsline.com
CNSPCns Pharmaceuticals Inc Stock Price and Quote - Finviz
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight - GlobeNewswire Inc.
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) registers 9.79M resale shares from May private placement - Stock Titan
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Bluefield Daily Telegraph
Insider Buying: Faith Charles Acquires Shares of CNS Pharmaceuti - GuruFocus
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock - Investing.com
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):